1921
Volume 102, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

A vicious circle links lack of equitable access to health to the supply of poor-quality medicines, which amount to one-tenth of medicines available in low- and middle-income countries. The WHO introduced a new, public health–focused definition of substandard and falsified (SF) medicines, which offers opportunities for governments to broaden the scope of interventions to combat poor-quality medicines. At the same time, translating it into legal and regulatory measures may be challenging because this definition is not free of ambiguity (in that, there is a gray area between intentionally falsified and unintentional substandard medicines), and some countries may not have appropriate regulatory mechanisms/jurisdictions in place. The focus of the article is to consider what a public health–informed legal and regulatory environment could look like in light of WHO’s SF definition and propose appropriate measures to put it into effect. We present a “legal levers matrix” that may assist legislators and policymakers evaluate the adequacy of measures (i.e., criminal, civil, and administrative mechanisms) to address the problem of poor-quality medicines, particularly in terms of their configuration. In addition, this matrix underscores the importance of fostering dialogue between medical/public health and the legal/regulatory communities and to develop alternative/complementary solutions, including regulatory strengthening and nonpunitive actions. Substandard and falsified medicines arise from the interplay between societies, economies, and behaviors: effective regulation is necessary to disincentivize the production and/or supply of SF medicines, whereas health systems should strive to provide affordable medicines to all levels of society.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.19-0645
2019-11-18
2020-02-17
Loading full text...

Full text loading...

/deliver/fulltext/14761645/102/2/tpmd190645.html?itemId=/content/journals/10.4269/ajtmh.19-0645&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2017. WHO Global Surveillance and Monitoring System for Substandard and Falsified Medical Products. Geneva, Switzerland: WHO. [Google Scholar]
  2. Caudron J-M, Ford N, Henkens M, Macé C, Kiddle-Monroe R, Pinel J, , 2008. Substandard medicines in resource-poor settings: a problem that can no longer be ignored. Trop Med Int Health 13: 10621072. [Google Scholar]
  3. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Guerin PJ, White NJ, , 2011. The primacy of public health considerations in defining poor quality medicines. PLoS Med 8: e1001139. [Google Scholar]
  4. Johnston A, Holt DW, , 2014. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol 78: 218243. [Google Scholar]
  5. Ozawa S, Evans DR, Bessias S, Haynie DG, Yemeke TT, Laing SK, Herrington JE, , 2018. Prevalence and estimated economic burden of substandard and falsified medicines in low- and middle-income countries. JAMA Netw Open 1: e181662. [Google Scholar]
  6. Nayyar GML, Breman JG, Mackey TK, Clark JP, Hajjou M, Littrell M, Herrington JE, , 2019. Falsified and substandard drugs: stopping the pandemic. Am J Trop Med Hyg 100: 10581065. [Google Scholar]
  7. World Health Organization, 2017. Definitions of Substandard and Falsified (SF) Medical Products. Available at: https://www.who.int/medicines/regulation/ssffc/definitions/en/. Accessed November 5, 2019. [Google Scholar]
  8. World Health Assembly (WHA), 2014. Resolution WHA67.20. Regulatory System Strengthening for Medical Products . Sixty-Seventh WHA, May 19–24, 2014, Geneva, Switzerland: World Health Organization. Available at: http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R20-en.pdf. Accessed November 5, 2019. [Google Scholar]
  9. Sunyoto T, Potet J, Boelaert M, , 2018. Why miltefosine—a life-saving drug for leishmaniasis—is unavailable to people who need it the most. BMJ Glob Health 3. [Google Scholar]
  10. Dorlo TPC, Eggelte TA, Schoone GJ, Vries PJD, Beijnen JH, , 2012. A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal. PLoS Negl Trop Dis 6: e1544. [Google Scholar]
  11. WHO Alert , 1940. The Drugs Act, Bangladesh.
  12. World Health Organization, 2012. Drug Safety Alert, Number 125. Available at: http://www.who.int/medicines/publications/drugalerts/DrugSafetyAlert125.pdf. Accessed November 5, 2019. [Google Scholar]
  13. Judicial Inquiry Tribunal, 2012. Batch J093, the Pathology of Negligence. Lahore, Pakistan. [Google Scholar]
  14. Lancet T, , 2018. Vaccine scandal and confidence crisis in China. Lancet 392: 360. [Google Scholar]
  15. Lehmann A, Hofsäss M, Dressman J, , 2018. Differences in drug quality between South Africa and Germany. J Pharm Pharmacol 70: 13011314. [Google Scholar]
  16. Attaran A, , 2015. Stopping murder by medicine: introducing the model law on medicine crime. Am J Trop Med Hyg 92 (Suppl 6): 127132. [Google Scholar]
  17. ‘t Hoen E, Pascual F, , 2015. Viewpoint: counterfeit medicines and substandard medicines: different problems requiring different solutions. J Public Health Policy 36: 384389. [Google Scholar]
  18. World Health Organization, 2018. WHO Global Benchmarking Tool (GBT) for Evaluation of National Regulatory System of Medical Products National Regulatory System (RS): Indicators and Fact Sheets. Available at: https://www.who.int/medicines/areas/regulation/01_GBT_RS_RevVI.pdf?ua=1. Accessed November 5, 2019. [Google Scholar]
  19. Medicines Regulation, 2016. Comparison of medicines legislation in the east African community. WHO Drug Inf 30: 567576. [Google Scholar]
  20. Zarocosta J, , 2019. Health ministers adopt African medicines agency treaty. Lancet 391:2310. [Google Scholar]
  21. Anonymous, 2017. Negligence. Legal Information Institute. Available at: https://www.law.cornell.edu/wex/negligence.
  22. World Health Organization, 2018. Medicines Regulatory Support. Available at: https://www.who.int/medicines/areas/quality_safety/regulation_legislation/en/. [Google Scholar]
  23. Legal person. Definition of legal person by Lexico. Lexico Dictionaries | English. Available at: https://en.oxforddictionaries.com/definition/legal_person. [Google Scholar]
  24. Anonymous. 2015. Intent. Legal Information Institute. Available at: https://www.law.cornell.edu/wex/intent.
  25. Garner BA, . 2014. Blacks Law Dictionary. St. Paul, MN: Thomson Reuters. [Google Scholar]
  26. Koyuncu A, Kirch W, . 2008. Administrative Law and Public Health. , ed. Encyclopedia of Public Health. Dordrecht, The Netherlands: Springer. [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.19-0645
Loading
/content/journals/10.4269/ajtmh.19-0645
Loading

Data & Media loading...

  • Received : 30 Aug 2019
  • Accepted : 22 Oct 2019
  • Published online : 18 Nov 2019

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error